OVERVIEW OF MYELOPROLIFERATIVE NEOPLASMS

Authors

  • Aghssan Saadoun Jemil Department of Pathology, College of Medicine, Babylon University, Babylon, Iraq
  • Liqaa Mohammad Majeed Department of Pathology, College of Medicine, Babylon University, Babylon, Iraq
  • Athraa Falah Alshimerry Department of Pathology, College of Medicine, Babylon University, Babylon, Iraq

Keywords:

MPN, polycythemia vera essential thrombocythemia, myelofibrosis, splenomegaly

Abstract

Background: Classical (Philadelphia –ve) MPNs are a diverse category of hematologic cancers that include essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), and post-PV-MF and post-ET-MF. One of the leading causes of morbidity and mortality is the progression to more symptomatic disease, such as overt MF or acute leukemia. MPN progression can be clinically visible or subclinically visible. Clinically visible progression includes transition from ET to PV, ET to post-ET-MF, PV to post-PV-MF, or pre-PMF to overt PMF, as well as transformation to myelodysplastic neoplasms or acute leukemia from any of these subtypes. Increases in the degree of bone marrow fibrosis, increases in driver gene mutational allele burden, and clonal evolution are examples of subclinical kinds of development.

Objectives: this study include heamatological assessment of myeloproliferative neoplasms subtypes

Material and Methods: 60 Iraqi patients diagnosed as myeloproliferative neoplasms including (20) cases of polycythemia vera, (20) cases of essential thrombocythemia , (20) cases of primary myelofibrosis and 10 cases including control group which had been referred to and evaluated in pathology department in Baghdad medical city between 2019 and 2022 are included in this study for hematological and clinical evaluation of MPNs subtypes.

Results: Splenomegaly was positive in half of patients with myeloproliferative neoplasms which represent 30 patients (50.0%) of total patients, There were significant differences between means of Hemoglobin (mg/dl) ,PCV,WBC.platelete according to subtypes of myeloproliferative neoplasms.

Conclusion: the percentage of splenomegaly was significantly higher in patients with myelofibrosis which was 90% than those with polycythemia Vera and essential thrombocythemia which 20% and 40% respectively. While PCV and Hb were significantly higher in patients with polycythemia Vera, there was significant increase in WBC count in patients with PV than in ET and PMF, and regarding platelet count it was higher in patients with ET than other subtypes.

Downloads

Published

2023-08-04

How to Cite

Aghssan Saadoun Jemil, Liqaa Mohammad Majeed, & Athraa Falah Alshimerry. (2023). OVERVIEW OF MYELOPROLIFERATIVE NEOPLASMS. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 3(8), 11–19. Retrieved from https://inovatus.es/index.php/ejmmp/article/view/1915

Similar Articles

<< < 1 2 3 4 

You may also start an advanced similarity search for this article.